Your browser doesn't support javascript.
loading
Simvastatin prevents lipopolysaccharide-induced septic shock in rats.
Yu, Li; Da, Xing-Wen; Wu, Xiao-Ling; He, Ao-di; Long, Ding.
Afiliación
  • Yu L; Intensive Care Unit, Wuhan Central Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430014, China. yuli641006@sina.com.
  • Da XW; Department of Pharmacology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
  • Wu XL; Intensive Care Unit, Wuhan Central Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430014, China.
  • He AD; Department of Pharmacology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
  • Long D; Intensive Care Unit, Wuhan Central Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430014, China.
J Huazhong Univ Sci Technolog Med Sci ; 37(2): 226-230, 2017 Apr.
Article en En | MEDLINE | ID: mdl-28397043
Simvastatin is a hypolipidemic drug that inhibits hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase to control elevated cholesterol, or hypercholesterolemia. Previous studies have shown that simvastatin may attenuate inflammation in ischemia-reperfusion injury and sepsis. Herein, we hypothesized that simvastatin may prevent rats from lipopolysaccharide (LPS)-induced septic shock. In our study, rats were divided into a saline group, an LPS group and an LPS plus simvastatin group. Male Sprague-Dawley (SD) rats were pretreated with simvastatin (1 mg/kg) for 30 min before the addition of LPS (8 mg/kg), with variations in left ventricular pressure recorded throughout. Ninety min after LPS injection, whole blood was collected from the inferior vena cava, and neutrophils were separated from the whole blood using separating medium. The neutrophils were then lysed for Western blotting to detect the levels of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1). In addition, mesentery microcirculations of inlet diameter, outlet diameter and blood flow rate were measured in all three groups. The results indicated that simvastatin significantly promoted heart systolic function and increased the level of uPA while simultaneously inhibited the expression of PAI-1 as compared with LPS group. Moreover, simvastatin reversed the LPS-induced inhibition of mesentery microcirculation. Taken together, it was suggested that simvastatin can effectively protect the rats from LPS-induced septic shock.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Choque Séptico / Activador de Plasminógeno de Tipo Uroquinasa / Lipopolisacáridos / Inhibidor 1 de Activador Plasminogénico / Simvastatina Límite: Animals Idioma: En Revista: J Huazhong Univ Sci Technolog Med Sci Asunto de la revista: MEDICINA Año: 2017 Tipo del documento: Article País de afiliación: China Pais de publicación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Choque Séptico / Activador de Plasminógeno de Tipo Uroquinasa / Lipopolisacáridos / Inhibidor 1 de Activador Plasminogénico / Simvastatina Límite: Animals Idioma: En Revista: J Huazhong Univ Sci Technolog Med Sci Asunto de la revista: MEDICINA Año: 2017 Tipo del documento: Article País de afiliación: China Pais de publicación: China